The Concept and Reality of Precision Medicine

Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.

Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.

New results for lung and pancreatic cancer show newer targeted drugs may help some patients live longer. Here is what patients and caregivers should know.

An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.

Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.

A study found that 1 in 9 older cancer survivors developed a second cancer, highlighting why routine screening remains important beyond five years.

After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.

A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.